Key result
Alzheimer's disease shows no significant difference in HEV seroprevalence versus non-AD cognitive impairment.
Why the study?
Hepatitis E virus exposure has been linked to neurologic manifestations and dementia, prompting investigation into a possible association between HEV and Alzheimer's disease.
Is prior HEV infection associated with Alzheimer's disease in cognitively impaired adults?
Case-Control (n=453)
No
Is prior HEV infection associated with Alzheimer's disease in cognitively impaired adults?
Answers are grounded in this paper and cite their sources.
Anti-HEV antibodies are more frequent in younger elderly AD patients compared with cognitively impaired individuals of the same age without AD, suggesting HEV infection may be an environmental risk factor for AD.
Background Hepatitis E virus (HEV) exposure has been linked to neurologic manifestations and dementia. This study aims to clarify a possible association between HEV and Alzheimer’s disease (AD). Methods We performed a single-center retrospective case–control study of 453 cognitively impaired adults from southern Germany, comparing anti-HEV IgG seropositivity between patients with AD and those with non-AD cognitive impairment. Associations were evaluated using chi-square testing and multivariable logistic regression, including age-stratified analyses. Results Overall HEV IgG seroprevalence was higher in the AD group than in the non-AD group (44.5% vs. 37.7%, p = 0.138), with a significant difference in patients aged 60–69 years (46.5% vs. 35.1%, p = 0.040) but not in those aged 70–79 years (46.7% vs. 50.0%, p = 0.646). Conclusion These findings suggest that anti-HEV antibodies are more frequent in younger elderly AD patients compared with cognitively impaired individuals of the same age without AD, raising the hypothesis that prior HEV infection may represent a candidate environmental risk factor for AD.
No takes yet. Share an insight, caveat, or question.
Capraru et al. (2026) conducted a case-control in Alzheimer's disease (n=453). Alzheimer's disease vs. Non-AD cognitive impairment was evaluated on Overall HEV IgG seroprevalence (p=0.138). Alzheimer's disease patients had an overall anti-HEV IgG seroprevalence of 44.5% compared to 37.7% in patients with non-AD cognitive impairment.
Synapse has enriched 10 related papers. Consider them for comparative context: